Column Capital Advisors’s Teva Pharmaceutical Industries Limited TEVA Stock Holding History

Column Capital Advisors’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$1.45K	Buy	+142	New	+$1.32K	﹤0.01%	711
2022 Q2	–	Sell	-199	Closed	-$2K	–	742
2022 Q1	$2K	Hold	199	–	–	﹤0.01%	663
2021 Q4	$2K	Hold	199	–	–	﹤0.01%	678
2021 Q3	$2K	Hold	199	–	–	﹤0.01%	643
2021 Q2	$2K	Hold	199	–	–	﹤0.01%	644
2021 Q1	$2K	Hold	199	–	–	﹤0.01%	633
2020 Q4	$2K	Buy	+199	New	+$1.91K	﹤0.01%	620
2020 Q3	–	Sell	-112	Closed	-$1K	–	858
2020 Q2	$1K	Buy	+112	New	+$1.27K	﹤0.01%	795

Other funds holding TEVA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

IAM

Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return

SPC

Slate Path Capital New York $7.22B AUM 110.75% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Column Capital Advisors's TEVA Position: Q3 2023 in Review

Column Capital Advisors opened a new position in Teva Pharmaceutical Industries Limited (TEVA) in Q3 2023: 142 shares worth $1.45K. The stake represents ﹤0.01% of the portfolio and ranks #711 among its holdings. This is a return to the name: Column Capital Advisors previously reported a position in TEVA as recently as Q1 2022.

Column Capital Advisors first reported a position in TEVA in Q2 2020 and has held it in 8 quarters since. The position peaked at $2K in Q1 2022. 435 funds tracked by Wall St. Rank hold TEVA as of Q3 2023.

Column Capital Advisors held 142 shares of Teva Pharmaceutical Industries Limited worth $1.45K as of Q3 2023.
Teva Pharmaceutical Industries Limited was a new Column Capital Advisors position in Q3 2023.
Teva Pharmaceutical Industries Limited made up ﹤0.01% of Column Capital Advisors's portfolio in Q3 2023, its #711 holding.
Column Capital Advisors first reported a position in Teva Pharmaceutical Industries Limited in Q2 2020 and has held it in 8 quarters since.
Column Capital Advisors's Teva Pharmaceutical Industries Limited position peaked at $2K in Q1 2022.
435 funds tracked by Wall St. Rank held Teva Pharmaceutical Industries Limited as of Q3 2023.

Based on Column Capital Advisors's 13F filing for Q3 2023, filed 3 Nov 2023.